OptiNose, a provider of bi-directional nasal activity technology, has released positive Phase II trial results evaluating the bi-directional nasal device delivering fluticasone, a nasal steroid, which demonstrated to be effective in progressively reducing the size or eliminating nasal polyps in patients with chronic rhinosinustis (CRS) with nasal polyps.
